Cited 10 times in
Involved-field radiation therapy for selected cases of recurrent ovarian cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김건민 | - |
dc.contributor.author | 김나리 | - |
dc.contributor.author | 김상운 | - |
dc.contributor.author | 김용배 | - |
dc.contributor.author | 이정은 | - |
dc.contributor.author | 장지석 | - |
dc.date.accessioned | 2019-12-18T01:06:35Z | - |
dc.date.available | 2019-12-18T01:06:35Z | - |
dc.date.issued | 2019 | - |
dc.identifier.issn | 2005-0380 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/173369 | - |
dc.description.abstract | OBJECTIVES: In our institutional experience, involved-field radiation therapy (IFRT) yields favorable outcomes in patients with recurrent epithelial ovarian cancer (EOC). This retrospective study aimed to investigate the clinical benefits of IFRT in this patient population. METHODS: Among patients treated with IFRT for recurrent EOC between 2010 and 2017, 61 patients with 90 treatments were included. IFRT encompassed all treatable lesions identified via imaging studies with 10-15-mm margins. Prescribed doses were ≥45 Gy (equivalent dose in 2 Gy/fraction). RESULTS: Patients were followed up for a median of 19.0 (Interquartile range, 8.6-34.9) months after IFRT. The 2-year in-field control, progression-free survival, and overall survival (OS) rates were 42.7%, 24.2%, and 78.9%, respectively. Fifty-three IFRT sessions (58.9%) were followed by systemic chemotherapy, and the median chemotherapy-free interval (CFI) was 10.5 (95% confidence interval=7.3-13.7) months. A higher carbohydrate antigen-125 (CA-125) level correlated with a worse 2-year OS (69.2% vs. 91.0%; p=0.001) and shorter median CFI (4.7 vs. 11.9 months; p<0.001). Twenty-eight (31.1%) of 90 treatments yielded a long-term CFI >12 months. For patients with a normal CA-125 level and/or platinum-sensitive tumor, IFRT prolonged CFI regardless of pre-existing carcinomatosis, gross tumor volume, and number of treatment sites. CONCLUSION: Our early experience demonstrates the safety and feasibility of IFRT as an effective salvage therapy and enables a "chemotherapy holiday" in selected recurrent EOC settings. The CA-125 value before IFRT (within normal range) and/or platinum sensitivity could be used as selection criteria for IFRT. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Asian Society of Gynecologic Oncology : Taehan Puin Chongyang Hakhoe | - |
dc.relation.isPartOf | JOURNAL OF GYNECOLOGIC ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Involved-field radiation therapy for selected cases of recurrent ovarian cancer | - |
dc.title.alternative | . | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Nalee Kim | - |
dc.contributor.googleauthor | Jee Suk Chang | - |
dc.contributor.googleauthor | Sang Wun Kim | - |
dc.contributor.googleauthor | Gun Min Kim | - |
dc.contributor.googleauthor | Jung-Yun Lee | - |
dc.contributor.googleauthor | Yong Bae Kim | - |
dc.identifier.doi | 10.3802/jgo.2019.30.e67 | - |
dc.contributor.localId | A00287 | - |
dc.contributor.localId | A05709 | - |
dc.contributor.localId | A00526 | - |
dc.contributor.localId | A00744 | - |
dc.contributor.localId | A03119 | - |
dc.contributor.localId | A04658 | - |
dc.relation.journalcode | J01428 | - |
dc.identifier.eissn | 2005-0399 | - |
dc.identifier.pmid | 31328453 | - |
dc.subject.keyword | CA-125 Antigen | - |
dc.subject.keyword | Ovarian Cancer | - |
dc.subject.keyword | Platinum Sensitivity | - |
dc.subject.keyword | Radiation Therapy | - |
dc.subject.keyword | Recurrent | - |
dc.contributor.alternativeName | Kim, Gun Min | - |
dc.contributor.affiliatedAuthor | 김건민 | - |
dc.contributor.affiliatedAuthor | 김나리 | - |
dc.contributor.affiliatedAuthor | 김상운 | - |
dc.contributor.affiliatedAuthor | 김용배 | - |
dc.contributor.affiliatedAuthor | 이정은 | - |
dc.contributor.affiliatedAuthor | 장지석 | - |
dc.citation.volume | 30 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | e67 | - |
dc.identifier.bibliographicCitation | JOURNAL OF GYNECOLOGIC ONCOLOGY, Vol.30(5) : e67, 2019 | - |
dc.identifier.rimsid | 63859 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.